Analysts Offer Insights on Rapport Therapeutics and Honeywell Aerospace
Rapport Therapeutics and Honeywell Aerospace have received recent analyst updates. Goldman Sachs' Salveen Richter maintained a Buy rating on Rapport Therapeutics with a price target of $62.00, citing its epilepsy pipeline.
According to TipRanks, Richter is a 5-star analyst with an average return of 12.1% and a 50.5% success rate. The healthcare sector has seen a Strong Buy consensus rating for Rapport Therapeutics, Inc., with an average price target of $54.43, representing a 31.4% upside from current levels.
William Blair also initiated coverage on the stock with a Buy rating in July. In contrast, UBS analyst Gavin Parsons maintained a Hold rating on Honeywell Aerospace and set a price target of $213.00, which is close to its 52-week low of $192.03.